The combination of belzutifan (WELIREG) plus lenvatinib (LENVIMA) met the primary endpoint of progression-free survival in the Phase 3 LITESPARK-011 trial in patients with previously treated advanced clear cell renal cell carcinoma. The regimen demonstrated a statistically significant and clinically meaningful PFS benefit with higher objective response rates versus cabozantinib, supporting its potential role as a novel post-immunotherapy treatment option.

GLP-1 agonists in mRCC patients showed 51% lower mortality and reduced immune toxicity with checkpoint inhibitors in 994-patient analysis.

68Ga-NY104 PET/CT shows better diagnostic efficacy than 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma.